The iLite® Etanercept NAb positive control can be used as a positive control for neutralizing antibodies against Etanercept.
Application Notes for the following assays are available:
• Determination of neutralizing antibodies against TNF-alpha blockers using iLite® TNF-alpha Assay Ready Cells (E-174-GB)
Tumor necrosis factor alpha (TNF-alpha) promotes inflammatory responses, which, in turn, contribute to the clinical problems associated with many inflammatory disorders, including rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, psoriasis and refractory asthma. These diseases are sometimes treated with TNF-alpha inhibitors, including infliximab, adalimumab, etanercept, certolizumab pegol or golimumab. Prolonged therapies with these TNF-alpha inhibitors may lead to development of neutralizing antibodies (NAbs), which may counteract the TNF-alpha antagonist activity of the drugs.
75 µL of iLite® Etanercept NAb positive control diluted in RPMI 1640 with 40% heat inactivated normal human serum (NHS).
